Clinical Trial Update: Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on epicardial delivery of XC001 gene therapy for refractory angina in the EXACT trial (Phase 1/2), completed to date.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Ischemia

Drugs mentioned

• XC001

Snippet

Sponsor: XyloCor Therapeutics, Inc. | Conditions: Coronary Artery Disease, Ischemia | Phase 1, Phase 2 | Status: COMPLETED